



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 38/55	A1	(11) International Publication Number: WO 96/16671	(43) International Publication Date: 6 June 1996 (06.06.96)
--	----	---	--

(21) International Application Number: PCT/SE95/01425

(22) International Filing Date: 29 November 1995 (29.11.95)

(30) Priority Data:
9404196-9 2 December 1994 (02.12.94) SE(71) Applicant (for all designated States except US): ASTRA
AKTIEBOLAG [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): LÖFROTH, Jan-Erik
[SE/SE]; Ringleken 13, S-431 69 Mölndal (SE). UNGELL,
Anna-Lena [SE/SE]; Tingvallsvägen 7, S-416 76 Göteborg
(SE).(74) Agent: ASTRA AKTIEBOLAG; Patent Dept., S-151 85
Södertälje (SE).(81) Designated States: AL, AM, AT, AU, BB, BG, BR, BY, CA,
CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP,
KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG,
MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European
patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE,
LS, MW, SD, SZ, UG).

Published

With international search report.

(54) Title: NEW ANTITHROMBOTIC FORMULATION, PROCESS FOR ITS MANUFACTURING, AND USE THEREOF

(57) Abstract

A new pharmaceutical formulation comprising the thrombin inhibitor $\text{HOOC-CH}_2\text{-(R)-Cgl-Aze-Pab}$ in combination with one or more absorption enhancing agents, a process for the preparation of such a pharmaceutical formulation, the use of such a formulation in the treatment of thromboembolism as well as a method of treating a patient in need of antithrombotic treatment and thromboembolism by using said formulation.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

New antithrombotic formulation, process for its
manufacturing, and use thereof
Field of the invention

The present invention relates to a new pharmaceutical
5 formulation comprising the thrombin inhibitor $\text{HOOC-CH}_2\text{-}$
(R)-Cgl-Aze-Pab in combination with one or more
absorption enhancing agents, a process for the
preparation of such a pharmaceutical formulation, and
the use of such a formulation in the treatment of
10 thromboembolism as well as a method of treating a
patient in need of such a treatment by using said
formulation.

BACKGROUND

15 Blood coagulation is the key process involved in both
haemostasis (i.e. prevention of blood loss from a
damaged vessel) and thrombosis (i.e. the pathological
occlusion of a blood vessel by a blood clot).

20 Coagulation is the result of a complex series of
enzymatic reactions; one of the final steps is
conversion of the proenzyme prothrombin to the active
enzyme thrombin.

25 Thrombin plays a central role in coagulation. It
activates platelets, it converts fibrinogen into fibrin
monomers, which polymerize spontaneously into
filaments, and it activates factor XIII, which in turn
crosslinks the polymer to insoluble fibrin. Thrombin
30 further activates factor V and factor VIII in a
positive feedback reaction. Inhibitors of thrombin are
therefore expected to be effective anticoagulants by
inhibition of platelet activation, fibrin formation and
fibrin stabilization. By inhibiting the positive
35 feedback mechanism such inhibitors are expected to
exert inhibition early in the chain of events leading

to coagulation and thrombosis.

Peptidic or peptide like thrombin inhibitors, like many other peptide-like substances, are prone to limited or variable absorption when administered. This is due to the influence of different barriers of metabolic and physical character, such as enzymatic degradation, tendencies toward complex formation with components from the formulation or the biological environment, limitations in transport possibilities etc. One object of the present pharmaceutical formulation is to facilitate for the active agent to overcome such barriers, and to obtain an enhanced and reproducible absorption of the active agent. Formulation components that have such influence and thus can help the active agent are called absorption enhancers.

Prior Art

Concerning the use of absorption enhancers in pharmaceutical formulations, several reports and reviews in the literature exist. Enhancing properties have been reported of different types of substances, such as surface active agents and lipids, chelators, and polymers. Comprehensive reviews have been presented by E J van Hoogdalem et al., Pharmac Theor vol 44, 407-443 (1989), by S Muranishi, Crit Rev Ther Drug Carrier Syst vol 7, 1-33 (1990), by E S Swenson and W J Curatolo, Adv Drug Deliv Rev vol 8, 39-92 (1992), and in Drug Absorption Enhancement (Ed.: A B G de Boer), Harwood Academic Publishers 1994.

DISCLOSURE OF THE INVENTION

It has been found that the absorption of the therapeutically active thrombin inhibitor $\text{HOOC-CH}_2\text{-(R)-Cgl-Aze-Pab}$ can be modified by incorporating enhancing

agents in the pharmaceutical formulations containing said therapeutically active compound.

Therefore, an object of the present invention is to provide novel pharmaceutical formulations comprising the thrombin inhibitor $\text{HOOC-CH}_2\text{-(R)-Cgl-Aze-Pab}$ in combination with one or more absorption enhancing agents and optionally a pharmaceutically acceptable carrier, and a process for the preparation of such pharmaceutical formulations.

Means of obtaining improved formulations of this therapeutically active drug are based on the use of absorption enhancing agents, such as, but not limited to, surface active agents, lipids, other drugs and polymers to obtain positive effects which result in an enhanced and/or less variable absorption of the therapeutically active agent when said agent is given by different administration routes, such as oral, rectal, buccal, nasal, pulmonary, inhalation route etc., and combinations of such agents to obtain even positive synergistic effects which result in even higher enhanced absorption.

The absorption enhancing effects described in this invention are meant to be obtained by one or more additives in the formulation, such as, but not limited to:

Non-steroidal anti-inflammatory drugs and derivatives, such as sodium salicylate, sodium 5-methoxysalicylate, indomethacin and diclofenac;

Surfactants, such as nonionic surfactants, e.g., sorbitan esters (Span series), polysorbates (Tween series), poloxyethylated glycol monoethers (like the Brij series), polyoxylated alkyl esters (Myrj series), polyoxyethylated

alkyl phenols (like the Triton series), alkyl glucosides like sugar glycosides, e.g., dodecylmaltoside, sugar fatty acid esters, e.g., sucrose laurate, sucrose monostearate etc and saponins;

5 ampholytic surfactants, e.g., betaines; anionic surfactants, e.g., sulphated fatty alcohols, sulphated polyoxyethylated alcohols, others like dioctyl sulphosuccinate;

10 cationic surfactants, e.g., ammonium compounds. Bile salts, such as dihydroxy bile salts like sodium deoxycholate, trihydroxy bile salts like sodium glycocholate and fusidates, e.g., sodium dihydrofusidate;

15 Soaps and fatty acids, and their salts, e.g. octanoic acid, decanoic acid and sodium decanoate;

20 Lipids, such as glycerides, e.g., glycerylmonooctanoate and glycerylmonoolein; phospholipids, e.g., DPPC and DMPC; Oils, e.g., soy bean oil and sunflower oil; Enamines, such as DL-phenylalanine and ethylacetoacetate enamine;

25 Chelating agents, e.g., EDTA, EGTA, and citric acid;

Phenothiazines, such as chlorpromazine; Fatty acid derivatives of carnitine and peptides, e.g., palmitoyl-DL-carnitine and N-myristoyl-L-propyl-L-prolyl-glycinate;

30 Other substances, e.g., azone, concanavalin A, phosphate and phosphonate derivatives such as DL- α -glycerophosphate and 3-amino-1-hydroxypropylidene-1,1-diphosphonate, diethyl maleate and diethylethoxymethylene malonate;

35 Products from Maillard reactions, e.g., compounds from a glucoselysine reaction; Polymers, such as polyacrylic acids, e.g.,

Carbopol , polycarbophil; chitosan and chitosan derivatives; and block copolymers, e.g., poloxamers, poloxamines, and meroxapols.

5 Suitable intended combinations of the enhancing agents are, but are not limited to:

 Lipids and bile salts, e.g., monoolein and sodium taurocholate;

10 Lipids and phospholipids, e.g., medium chain glycerides and lecithins;

 Surfactants and oils, e.g., sucrose fatty acid esters and soy bean oil; and

15 Polymers and lipids, e.g., polycarbophil and monoolein.

The dosage form used may be a solid, semisolid or liquid preparation prepared by known techniques.

20 Usually the active substance will constitute between 0.1 and 99 % by weight of the preparation, more specifically between 0.1 and 50 % by weight for preparations intended for parenteral administration and between 0.2 and 90 % by weight for preparations suitable for oral administration.

25 Suitable daily doses of the therapeutically active drug in therapeutical treatment of humans are about 0.001-100 mg/kg body weight at peroral administration and 0.001-50 mg/kg body weight at parenteral administration.

30

35 The enhancing agent, or combinations of enhancing agents, will constitute between 0.1 and 99% by weight of the preparation. The formulations thus obtained will increase the absorption and/or minimize the variability of the absorption of the therapeutically active drug by different mechanisms.

The pharmaceutical formulations of the present invention comprising the modified dipeptide $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$ and the absorption enhancing agents are intended for prophylaxis and treatment in arterial as well as venous thromboembolism.

Another object of the invention is a process for the manufacturing of said pharmaceutical formulation comprising adding the absorption enhancing agents to a solution of a therapeutically active compound $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$, optionally adjusting the pH with a buffering agent to a therapeutically acceptable pH, for instance between 5 to 9, preferably between 7 and 8, e.g. 7.4 and mixing all ingredients. The buffering agent may be a phosphate buffer such as K_2HPO_4 : Na_2HPO_4 . Other ingredients conventionally used in pharmaceutical formulations such as carriers, isotonic agents such as NaCl known by a skilled person in the art may also be added to the pharmaceutical formulation of the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the effect of two absorption enhancing agents on the permeability of the intestinal membrane to $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$.

DETAILED DESCRIPTION OF THE INVENTION

The following description is illustrative of aspects of the invention.

EXPERIMENTAL PART

General experimental Procedures

Mass spectra were recorded on a Finnigan MAT TSQ 700 triple quadrupole mass spectrometer equipped with an

electrospray interface.

5 The ^1H NMR and ^{13}C NMR measurements were performed on
BRUKER AC-P 300 and BRUKER AM 500 spectrometers, the
former operating at a ^1H frequency of 500.14 MHz and a
 ^{13}C frequency of 125.76 MHz and the latter at ^1H and ^{13}C
frequency of 300.13 MHz and 75.46 MHz respectively.

10 The samples were about 10-50 mg dissolved in 0.6 ml of
one of the following solvents ; CDCl_3 (isotopic purity
> 99.8%), CD_3OD (isotopic purity > 99.95%) or D_2O
(isotopic purity > 99.98%). All solvents were purchased
from Dr. Glaser AG, Basel.

15 The ^1H and ^{13}C chemical shift values in CDCl_3 and CD_3OD
are relative to tetramethylsilane as an external
standard. The ^1H chemical shifts in D_2O are relative to
the sodium salt of 3-(trimethylsilyl)- d_4 -propanoic acid
and the ^{13}C chemical shifts in D_2O are referenced
20 relative to 1,4-dioxane (67.3 ppm), both as external
standard. Calibrating with an external standard may in
some cases cause minor shift differences compared to an
internal standard, however, the difference in ^1H
chemical shift is less than 0.02 ppm and in ^{13}C less
25 than 0.1 ppm.

The ^1H NMR spectrum of peptide sequences containing a
proline or a "proline like" residue frequently exhibits
two sets of resonances. This corresponds to the
30 existence of two contributing conformers with respect
to the rotation around the amide bond, where proline
contains the N-part of the amide bond. The conformers
are named *cis* and *trans*. In the compounds containing
such sequences the sequences (R)Cha-Aze- and (R)Cha-
35 Pic- often give rise to a *cis-trans* equilibrium with

one conformer as the preponderant conformer (>90%). In those cases only the ^1H chemical shifts of the major rotamer are reported. Only in the cases where the signals of the minor rotamer are clearly resolved are they reported in the NMR documentation. The same criterion is valid for the NH-signals in CDCl_3 , only in the cases where the signals are clearly resolved are they reported in the NMR-documentation. This implies that the number of protons reported for some of the intermediates is less than the number of protons expected from the chemical formula.

Flash chromatography was carried out on Merck Silica gel 60 (40-63 μm , 230-400 mesh) under pressure of air.

Freeze-drying was done on a Leybold-Heraeus, model Lyovac GT 2, apparatus.

Preparation of starting materials

4-aminomethyl-1-(N-benzyloxycarbonylamidino)-benzene (H-Pab(Z))

(i) 4-cyanobenzyl azide

A solution of 20.23 g (0.31 mol) sodium azide in 50 ml water was added to 49.15 g (251 mmol) 4-cyanobenzyl bromide in 200 ml DMF at ambient temperature. An exothermic reaction took place and after 1.5 h the reaction mixture was diluted with 200 ml toluene (caution: In order to avoid separation of potentially explosive azide compounds it is adviseable to add the toluene to the reaction mixture before addition of the water) and 500 ml water. The aqueous phase was extracted with an additional 2x50 ml toluene. The combined organic extracts were washed with 2x50 ml water and brine and finally dried (MgSO_4) and filtered.

The solution was used as such in the next step.

$^1\text{H-NMR}$ (300 MHz, CDCl_3); δ 4.4 (s, 2H), 7.4 (d, 2H), 7.7 (d, 2H).

5

(ii) 4-amidino benzyl azide

Hydrogen chloride was bubbled into a mixture of 250 ml absolute ethanol and the solution from step (i) (approximately 200 ml) above at -5°C until saturation. Storage at 8°C for 24 h and evaporation of most of the solvent followed by precipitation by addition of anhydrous ether gave white crystals which were isolated by filtration and dissolved in 1.8 l of alcoholic ammonia. After 48 h most of the solvent was removed and 200 ml 3.75 M NaOH solution was added whereupon 4-amidino benzyl azide precipitated as colourless crystals. The crystals were isolated by filtration. At this point the yield of 4-amidino benzyl azide was 22.5 g (total 51%).

10

15

20

Ethylimidatobenzyl azide hydrochloride:

$^1\text{H-NMR}$ (500 MHz, CD_3OD); δ 1.6 (t, 3H), 4.5 (s, 2H), 4.65 (q, 2H), 4.8 (br s, 2H), 7.6 (d, 2H), 8.1 (d, 2H)

25

4-amidino benzyl azide:

$^1\text{H-NMR}$ (500 MHz, CDCl_3); δ 4.3 (s, 2H), 5.7 (br s, 3H), 7.3 (d, 2H), 7.6 (d, 2H).

30

$^{13}\text{C-NMR}$ (125 MHz, CDCl_3): amidine carbon: δ 165.5.

(iii) 4-(benzyloxycarbonylamidino) benzyl azide

35

The crystals from (ii) above were dissolved in 500 ml

methylene chloride and the resulting solution was dried (K_2CO_3), filtered and 27 ml (194 mmol) triethyl amine was added. 25 ml Benzyl chloroformate was slowly added to the stirred solution while the reaction mixture was cooled in an ice bath. After 30 minutes an additional 2 ml benzyl chloroformate was added and stirring was continued for another 30 minutes. Subsequently, water was added and the aqueous phase was adjusted to pH 7 with 2M HCl. The organic phase was dried ($MgSO_4$) and the solvent was removed in vacuo. 4-(benzyloxycarbonylamidino) benzyl azide was finally isolated as colorless crystals from ether/methylene chloride/hexane.

1H -NMR (500 MHz, $CDCl_3$); δ 4.4 (s, 2H), 5.3 (s, 2H), 6.3-7.0 (br s, 1H), 7.3-7.4 (m, 5H), 7.5 (d, 2H), 7.9 (d, 2H), 9.3-9.6 (br s, 1H).

^{13}C -NMR (125 MHz, $CDCl_3$): amidine carbon: δ 167.5.

(iv) 4-aminomethyl-1-(N-benzyloxycarbonylamidino)-benzene (H-Pab(Z))

26.3 g (100 mmol) triphenylphosphine was added at room temperature to the 4-(benzyloxycarbonylamidino) benzyl azide from (iii) above dissolved in 160 ml THF. After 16 h an additional 6.6 g (25 mmol) triphenylphosphine was added and the solution was allowed to stand for 4 h before removal of the solvent in vacuo. The residue was dissolved in methylene chloride and extracted with 2M HCl. The aqueous phase was washed with methylene chloride and ether and was subsequently made alkaline with 3.75M sodium hydroxide solution. Extraction with methylene chloride followed by drying (K_2CO_3) and removal of the solvent in vacuo gave 20 g (The total yield starting from cyanobenzyl bromide is 28%) of a yellow oil which solidified on standing.

¹H-NMR (500 MHz, CDCl₃); δ 1.2-2.2 (br s, 2H), 3.8 (s, 2H), 5.2 (s, 2H), 7.2-7.35 (m, 5H), 7.4 (d, 2H), 7.8 (d, 2H), 9.1-9.6 (br s, 1H).

5 ¹³C-NMR (125 MHz, CDCl₃): amidine and carbonyl carbons: δ 164.6 and 168.17.

H-Aze-OMe x HCl

10 Prepared according to the procedure described by Seebach D. et. al. in Liebigs Ann. Chem., p. 687, 1990.

Boc-(R)Cgl-OH

15 Boc-(R)-Pgl-OH, 32.6 g (0.13 mol), was dissolved in 300 ml of methanol and 5 g of Rh/Al₂O₃ was added. The solution was hydrogenated at 5.2 to 2.8 MPa for 3 days. After filtration and evaporation of the solvent NMR showed the presence of about 25 % of the methyl ester
20 of the title compound. The crude material was dissolved in 500 ml of THF and 300 ml of water and 20 g of LiOH were added. The mixture was stirred overnight and the THF was evaporated. The remaining water phase was acidified with KHSO₄ and extracted three times with
25 ethyl acetate. The combined organic layer was washed with water, dried (Na₂SO₄) and evaporated to give 28.3 g (83 %) of the desired product.

30 ¹H-NMR (300 MHz, CDCl₃): δ 0.9-1.7 (m, 20H), 4.0-4.2 (m, 1H), 5.2 (d, 1H).

Boc-(R)Cgl-Aze-OH

(i) Boc-(R)Cgl-Aze-OMe

35

To a stirred mixture of 3.86 g (15 mmol) Boc-(R)Cgl-OH,

2.27 g (15 mmol) H-Aze-OMe x HCl and 2.75 g (22.5 mmol) DMAP in 40 mL CH₃CN at 5°C was added 3.16 g (16.5 mmol) EDC. The reaction mixture was stirred at room temperature for 48h. The solvent was evaporated and the residue was dissolved in 150 ml EtOAc and 20 ml H₂O. The separated organic layer was washed with 2 x 20 ml 0.5 M KHSO₄, 2 x 10 ml NaHCO₃(saturated), 1 x 10 ml H₂O, 1 x 10 ml brine and dried (MgSO₄). Evaporation of the solvent gave 4.91 g (92 %) of the title compound which was used without further purification in the next step.

¹H NMR (500 MHz, CDCl₃, 0.1 g/ml): major rotamer, 0.83-1.35 (m, 5H), 1.38 (s, 9H), 1.47-1.84 (m, 6H), 2.18-2.27 (m, 1H), 2.50-2.62 (m, 1H), 3.72 (s, 3H), 3.94-4.06 (m, 1H), 4.07-4.15 (m, 1H), 4.39-4.47 (m, 1H), 4.68 (dd, J=9.1, J=5.1, 1H), 5.09 (d, J=9.2, 1H). Resolved peaks from minor rotamer, 2.27-2.35 (m, 1H), 3.77 (s, 3H), 3.80-3.87 (m, 1H), 3.88-3.95 (m, 1H), 4.92 (d, J=9.2, 1H), 5.21 (dd, J=9.1, J=5, 1H).

(ii) Boc-(R)Cgl-Aze-OH

The hydrolysis of Boc-(R)Cgl-Aze-OMe was carried out according to the procedure described for Boc-(R)Cha-Pic-OEt (vide infra). The product was crystallized from EtOH/acetone/water (1/1/3.95) yield 80 %.

¹H-NMR (500 MHz, CDCl₃): δ 0.85-1.3 (m, 5H), 1.40 (s, 9H), 1.5-1.9 (m, 6H), 1.95-2.2 (m, 2H), 3.92 (m, 1H), 4.09 (m, 1H), 4.35 (m, 1H), 4.95 (m, 1H), 5.16 (bd, 1H).

Preparation of the compound HOOC-CH₂-(R)Cgl-Aze-Pab

(i) Boc-(R)Cgl-Aze-Pab(Z)

To a stirred mixture of 3.40 g (10 mmol) Boc-(R)Cgl-

Aze-OH (See Preparation of starting materials) and 5.13 g DMAP (42 mmol) in 120 ml CH_3CN was added 3.18 g H-Pab(Z) x HCl (See Preparation of starting materials). After stirring for 2 hours at room temperature the mixture was cooled to -8°C and 2.01 g (10.5 mmol) EDC was added. The reaction was allowed to reach room temperature and the stirring was continued for an additional 47 hours. The solvent was evaporated and the residue was dissolved in 200 ml EtOAc. The organic phase was washed with 1 x 50 ml water, 1 x 50 + 2 x 25 ml 0.5 M KHSO_4 , 2 x 25 ml NaHCO_3 (saturated), 1 x 50 ml water and dried. Evaporation of the solvent gave 5.21 g (86%) of the title compound.

$^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.8-1.9 (m, 20H; thereof 1.30 (s, 9H)), 2.35-2.6 (m, 2H), 3.74 (bt, 1H), 4.10 (m, 1H), 4.25-4.4 (m, 2H), 4.45-4.6 (m, 1H, rotamers), 4.75-5.0 (m, 1H, rotamers), 5.08 (bd, 2H), 5.15 (s, 2H), 7.15-7.35 (m, 5H), 7.41 (d, 2H), 7.77 (d, 2H), 8.21 (m, 1H).

(ii) H-(R)Cgl-Aze-Pab(Z)

To a cold (ice bath temperature) solution of 18.8 g $\text{HCl}_{(\text{g})}$ in 195 ml EtOAc was added 4.69 g (7.743 mmol) of Boc-(R)Cgl-Aze-Pab(Z) together with 40 ml EtOAc. The reaction mixture was allowed to reach room temperature and stirred for 30 min. 140 ml Et_2O was added to the clear solution where upon a precipitate was formed. The reaction was left at room temperature for an additional 1 h and 40 minutes. The precipitate was filtered off, washed quickly with 150 ml Et_2O and dried in vacuo. The precipitate was dissolved in 50 ml of water and made alkaline with 15 ml 2 M NaOH. The alkaline waterphase was extracted with 1 x 100 + 1 x 50 ml CH_2Cl_2 . The combined organic phase was washed with

1 x 20 ml water, 1 x 20 ml Brine and dried (MgSO_4).
Evaporation of the solvent gave 3.44 g (88%) of the
title compound.

5 $^1\text{H-NMR}$ (500 MHz, CDCl_3): δ 0.8-2.0 (m, 11H), 2.51 (m,
1H), 2.67 (m, 1H), 3.07 (d, 1H), 4.11 (m, 1H), 4.18 (m,
1H), 4.43 (dd, 1H), 4.53 (dd, 1H), 4.91 (m, 1H), 5.22
(s, 2H), 7.2-7.4 (m, 7H), 7.45 (d, 2H), 8.51 (d, 2H).

10 (iii) $\text{BnOOC-CH}_2\text{-(R)Cgl-Aze-Pab(Z)}$

1.13 g (2.2 mmol) H-(R)Cgl-Aze-Pab(Z), 0.9 g (2.6 mmol)
benzyl-2-(ortho-nitrobenzenesulfonyloxy)acetate ((2-
NO₂)Ph-SO₂-OCH₂-COOBn) (See Preparation of starting
15 materials), 0.99 g (5.6 mmol) K_2CO_3 and 113 ml CH_3CN
were mixed and heated in a 60°C oilbath for 3 h. The
solvent was evaporated in vacuo. EtOAc was added and
the mixture was washed with water, the organic phase
was extracted with 1 M KHSO_4 and this waterphase was
20 washed with EtOAc. The acidic waterphase was made
alkaline with 1 N NaOH to pH>8 and extracted with
EtOAc. The organic phase was washed with water, dried
(Na_2SO_4), filtered and evaporated in vacuo to give 1.17
g of a residue that was twice subjected to flash
25 chromatography using first $\text{CH}_2\text{Cl}_2/\text{MeOH}(\text{NH}_3\text{-saturated})$
95/5 and then diethylether/ $\text{MeOH}(\text{NH}_3\text{-saturated})$ 9/1 as
eluent to give 0.525 g (36 %) of the title compound.

The alkylation was also carried out using Benzyl-2-
30 (para-nitrobenzenesulfonyloxy)acetate ((4-NO₂)Ph-SO₂-
OCH₂-COOBn) (See Preparation of starting materials)
using the same procedure as above to give the title
compound in 52 % yield.

35 $^1\text{H-NMR}$ (300 MHz, CDCl_3): δ 0.85-2.15 (m, 11H), 2.48 (m,

1H), 2.63 (m, 1H), 2.88 (d, 1H), 3.24 (d, 1H), 3.27 (d, 1H), 3.95 (m, 1H), 4.05 (m, 1H), 4.44 (m, 1H), 4.55 (m, 1H), 4.91 (m, 1H), 5.07 (s, 2H), 5.22 (s, 2H), 7.2-7.4 (m, 10H), 7.45 (d, 2H), 7.79 (d, 2H), 8.42 (m, 1H).

5

(iva) $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab} \times 2 \text{ HCl}$

10 $\text{BnOOC-CH}_2\text{-(R)Cgl-Aze-Pab(Z)}$, 20 mg (0.031 mmol), was dissolved in 5 ml of methanol. A few drops of chloroform and 5 % Pd/C were added and the mixture was hydrogenated at atmospheric pressure for 1 h. After filtration and evaporation the product was lyophilized from water to give 11 mg (72%) of the title compound.

15 $^1\text{H-NMR}$ (500 MHz, D_2O): δ 1.0-2.0 (m, 11H), 2.10 (m, 1H), 2.44 (m, 1H), 2.82 (m, 1H), 3.90 (s, 2H), 4.09 (d, 1H), 4.4-4.55 (m, 2H), 4.66 (s, 2H), 5.08 (m, 1H), 7.65 (d, 2H), 7.89 (d, 2H).

20

$^{13}\text{C-NMR}$ (75.5 MHz, D_2O): amidine and carbonyl carbons: δ 167.3, 167.9, 169.9 and 172.4.

(ivb) $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$

25

$\text{BnOOC-CH}_2\text{-(R)Cgl-Aze-Pab(Z)}$ was dissolved in EtOH (99%) and hydrogenated over 5 % Pd/C at atmospheric pressure for 5 hours. Filtration of the catalyst through cellite and evaporation of the solvent gave the title compound in 97 % yield.

30

35 $^1\text{H-NMR}$ (500 MHz, CD_3OD , mixture of two rotamers): major rotamer: δ 1.00-1.12 (m, 1H), 1.13-1.34 (m, 4H), 1.55-1.70 (m, 3H), 1.73-1.85 (m, 2H), 1.94-2.02 (bd, 1H), 2.32-2.42 (m, 1H), 2.54-2.64 (m, 1H), 2.95-3.10 (AB-system plus d, 3H), 4.18-4.25 (bq, 1H), 4.28-4.32 (bq,

1H), 4.43-4.60 (AB-system, 2H), 4.80-4.85 (dd, 1H),
7.48-7.54 (d, 2H), 7.66-7.71 (d, 2H).

Resolved signals from the minor rotamer appear at δ
0.95 (m), 1.43 (m), 2.24 (m), 2.84 (d), 3.96 (m), 4.03
5 (m), 7.57 (bd), 7.78 (bd).

^{13}C -NMR (125 MHz, CD_3OD): amidine and carbonyl carbons:
 δ 168.0, 173.0, 176.3 and 179.0

10 Preparation of the formulations

Formulation A: $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$ (base) 1.1 mg/10ml
sucrose monostearate (S-1570) 1.1 mg/10 ml
phosphate buffer ($\text{KH}_2\text{PO}_4\text{:Na}_2\text{HPO}_4$) 0.1 M
15 pH 7.4 ad 10 ml

Formulation B: $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$ (base) 1.1 mg/10ml
sucrose monopalmitate (P-1570) 1.1 mg/10ml
phosphate buffer ($\text{KH}_2\text{PO}_4\text{:Na}_2\text{HPO}_4$) 0.1 M
20 pH 7.4 ad 10 ml

Formulations A and B were tested in rat colon segments
mounted in Ussing-chambers (described by Artursson et al,
Pharm. Research, vol.10 No.8 p 1123-29, (1993)). Samples
25 of the solution on both side of the membranes were
withdrawn at different time intervals and were analyzed
for the concentration of $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$. The
ability to cross the intestinal membrane was tested as an
indication of the permeability. The permeability
30 coefficient was calculated using the steady-state
appearance rate, dQ/dt of the compound on the serosal
side of the segments of the surface area, A , and the
initial concentration in the mucosal side, C_0 , according
to the equation $\text{Papp} = dQ/dt \cdot 1/AC_0$.

35 The results are shown in Figure 1. N in the figure

indicates the number of rats used. The results indicate that the permeability of the thrombin inhibitor HOOC-CH₂-(R)Cgl-Aze-Pab to cross the intestinal membrane into the circulation increase two to threefold compared to the control for both sucrose esters, the monostearate and the monopalmitate. The results thus substantiate the conclusion that the presence of such absorption enhancing agents increases the bioavailability of the therapeutically active agent.

10

ABBREVIATIONS

Aze = (S)-Azetidine-2-carboxylic acid

Cgl = (S)-Cyclohexyl glycine

15 Pab = 1-Amidino-4-aminomethyl benzene

CLAIMS

1. A pharmaceutical formulation comprising the
5 therapeutically active compound $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$ as
such or a stereoisomer thereof or a physiologically
acceptable salt thereof and one or more absorption
enhancing agents, and optionally a pharmaceutical
carrier.

10

2. A pharmaceutical formulation according to claim 1
wherein the absorption enhancing agent is a surfactant.

15

3. A pharmaceutical formulation according to claim 2
wherein the surfactant is an alkyl glycoside such as
sugar glycoside.

20

4. A pharmaceutical formulation according to claim 2
wherein the surfactant is a sugar fatty acid ester.

5. A pharmaceutical formulation according to claim 4
wherein the sugar fatty acid ester is sucrose
monostearate or sucrose monopalmitate.

25

6. A pharmaceutical formulation according to claim 1
wherein the absorption enhancing agent is a non-steroidal
antiinflammatory drug or a derivative thereof.

30

7. A pharmaceutical formulation according to claim 1
wherein the absorption enhancing agent is a bile salt.

8. A pharmaceutical formulation according to claim 1
wherein the absorption enhancing agent is a lipid.

35

9. A pharmaceutical formulation according to claim 1
wherein the absorption enhancing agent is a soap, a fatty
acid or a fatty acid derivative of carnitine or a

peptide.

10. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is an oil.

11. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is an enamine.

12. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is a chelating agent.

13. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is a phenothiazine.

14. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is a product from Maillard reactions.

15. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is a polymer.

16. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is azone, concanavalin A, phosphate or phosphonate derivative, diethyl maleate or diethylethoxymethylene malonate.

17. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is combination of lipids, a lipid and a phospholipid, a lipid and a bile salt, a lipid and an oil, a lipid and a surfactant, or a lipid and a polymer.

18. A pharmaceutical formulation according to claim 1 wherein the absorption enhancing agent is a combination of surfactants and oils.

19. A pharmaceutical formulation according to any one of the preceding claims wherein the active compound $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$ is in the form of the free base.

5 20. A process for the manufacturing of the pharmaceutical formulation defined in any one of the preceding claims characterized by adding an absorption enhancing agent to a solution of the compound $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$,
10 adjusting the pH by a buffering agent to a therapeutically acceptable pH and mixing all ingredients.

21. Use of a pharmaceutical formulation as defined in any one of the preceding claims 1-19 for the treatment of thromboembolism.

15 22. A method of treating a patient in need of antithrombotic treatment, comprising administering to said patient an effective amount of a pharmaceutical formulation as defined in any one of the claims 1-19.

20 23. A method for treatment of thromboembolism which comprises administering to a patient in need of such a treatment an effective amount of a pharmaceutical formulation as defined in any one of the claims 1-19.

25 24. A method for enhancing the absorption of the therapeutically active compound $\text{HOOC-CH}_2\text{-(R)Cgl-Aze-Pab}$ which comprises adding to the solution of said active compound an absorption enhancing agent selected from a
30 surfactant, an alkylglycoside, a sugar fatty acid ester, a bile salt, a lipid, a soap, a fatty acid or fatty acid derivative of carnitine, a peptide, a non-steriodal antiinflammatory drug, an oil, an enamine, a chelating agent, a phenothiazine, a polymer, a product from
35 Maillard reactions, an azone, concanavalin A, phosphate or phosphonate derivatives, diethyl maleate, diethylethoxymethylene malonate or combinations thereof,

optionally adjusting the pH with a buffering agent to a therapeutically acceptable pH and, mixing all the ingredients.


- 5 25. A method according to claim 24 wherein the absorption enhancing agent is selected from sucrose monostearate or sucrose monopalmitate.

THIS PAGE BLANK (USPTO)

1 / 1

Fig. 1

Permeability of *HOOC-CH₂-(R)-Cgl-Aze-Pab* in rat colon



THIS PAGE BLANK (USPTO)

A. CLASSIFICATION OF SUBJECT MATTER

IPC6: A61K 38/55

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC6: A61K, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REG, CA, WPI, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 9429336 A1 (ASTRA AKTIEBOLAG), 22 December 1994 (22.12.94) --	1-21
A	WO 9107976 A1 (BORER INTERNATIONAL (OVERSEAS) INC.), 13 June 1991 (13.06.91) --	1-21
A	WO 9311152 A1 (AKTIEBOLAGET ASTRA), 10 June 1993 (10.06.93) -- -----	1-21

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

14 March 1996

Date of mailing of the international search report

15 -03- 1996

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Car lina Gómez Lagerlöf
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 95/01425

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 22-25
because they relate to subject matter not required to be searched by this Authority, namely:
See PCT Rule 39.1(iv): Methods for treatment of the human or animal body by surgery or therapy, as well as diagnostic methods.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

05/02/96

International application No.

PCT/SE 95/01425

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO-A1-	9429336	22/12/94	NONE		
WO-A1-	9107976	13/06/91	AU-B-	636426	29/04/93
			AU-A-	6890091	26/06/91
			EP-A-	0502926	16/09/92
			JP-T-	5504762	22/07/93
			US-A-	5053392	01/10/91
WO-A1-	9311152	10/06/93	AP-A-	353	14/08/94
			AP-D-	9200457	00/00/00
			AU-A-	3120993	28/06/93
			CA-A-	2125175	10/06/93
			CN-A-	1076199	15/09/93
			CZ-A-	9401296	15/12/94
			EP-A-	0618926	12/10/94
			FI-A,D-	942645	03/06/94
			HU-A-	70431	30/10/95
			HU-D-	9401474	00/00/00
			NO-A,D-	942066	03/06/94
			SK-A-	63194	07/12/94
			ZA-A-	9209099	07/06/93

THIS PAGE BLANK (USPTO)